376 related articles for article (PubMed ID: 28914985)
1. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
3. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
4. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
5. SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.
Mukai T; Gallant R; Ishida S; Yoshitaka T; Kittaka M; Nishida K; Fox DA; Morita Y; Ueki Y
PLoS One; 2014; 9(8):e105518. PubMed ID: 25144740
[TBL] [Abstract][Full Text] [Related]
6. RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice.
Kittaka M; Yoshimoto T; Hoffman H; Levitan ME; Ueki Y
Bone Rep; 2020 Jun; 12():100258. PubMed ID: 32258251
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.
Yoshitaka T; Kittaka M; Ishida S; Mizuno N; Mukai T; Ueki Y
Bone; 2015 Feb; 71():201-9. PubMed ID: 25445458
[TBL] [Abstract][Full Text] [Related]
8. Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.
Kittaka M; Yoshimoto T; Schlosser C; Rottapel R; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2020 Feb; 35(2):382-395. PubMed ID: 31613396
[TBL] [Abstract][Full Text] [Related]
9. Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-κB signalling pathway.
Doss HM; Samarpita S; Ganesan R; Rasool M
Life Sci; 2018 Aug; 207():284-295. PubMed ID: 29908722
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
11. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
12. Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Kittaka M; Yoshimoto T; Schlosser C; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
JBMR Plus; 2020 Jun; 4(6):e10352. PubMed ID: 32537546
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
14. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
15. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
[TBL] [Abstract][Full Text] [Related]
17. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
18. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
19. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
20. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]